INHA acts as a novel and potential biomarker in lung adenocarcinoma and shapes the immune-suppressive tumor microenvironment
-
Published:2023-07
Issue:
Volume:33
Page:101679
-
ISSN:1936-5233
-
Container-title:Translational Oncology
-
language:en
-
Short-container-title:Translational Oncology
Author:
Zhang Xun,
Zhang Xinyu,
Jiang Dizhi,
Zheng Wendi,
Wang Huimin,
Tian Yu,
Cheng BoORCID
Subject
Cancer Research,Oncology
Reference60 articles.
1. Racial and ethnic variations in lung cancer incidence and mortality: results from the women's health initiative;Patel;J. Clin. Oncol.,2016
2. Cancer statistics, 2020;Siegel;CA Cancer J. Clin.,2020
3. A systematic dissection of the epigenomic heterogeneity of lung adenocarcinoma reveals two different subclasses with distinct prognosis and core regulatory networks;Yuan;Genome Biol.,2021
4. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship;Molina;Mayo Clin. Proc.,2008
5. A randomized, open-label, multicenter, phase 3 study to compare the efficacy and safety of eribulin to treatment of physician's choice in patients with advanced non-small cell lung cancer;Katakami;Ann. Oncol.,2017
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献